Provectus Biopharmaceuticals Announces Poster Presentation of Rose Bengal Sodium for Treatment of Full-Thickness Cutaneous Wounds at SID 2024 Annual Meeting

• Accelerates wound closure and improves wound healing
  

KNOXVILLE, TN, May 21, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that non-clinical data on Provectus’s proprietary, pharmaceutical-grade, rose bengal sodium (“RBS”) active pharmaceutical ingredient for the topical treatment of full-thickness cutaneous wounds were presented at the annual meeting of the Society for Investigative Dermatology (“SID”), held May 15-18, 2024 in Dallas, Texas.

This work is part of research being conducted by Amina El Ayadi, PhD, Assistant Professor, Surgical Sciences Division of the Burn, Trauma, and Critical Care Research Laboratory in the Department of Surgery at the University of Texas Medical Branch at Galveston (“UTMB”).

A copy of UTMB’s poster presentation is available here: https://www.provectusbio.com/media/docs/publications/SID-2024_Poster-P ....

The UTMB team and Dr. El Ayadi concluded that:

• The application of multidose 0.01% RBS every other day under ambient light (“RBS treatment”) to full-thickness wounds showed:
  • No toxicity or mortality,
  • No loss in body weight,
  • No organ abnormalities, and
  • No observed adverse effect level at the highest tested dose,
• Transepidermal water loss was significantly reduced by 14 days, suggesting improvement in skin barrier function,
• Erythema was increased at seven days, suggesting increased blood flow and granulation tissue formation required for wound healing,
• Vascularity was increased between three and seven days, supporting pro-angiogenic activity needed for wound closure,
• RBS treatment:
  • Accelerated wound closure (significant difference at three days),
  • Increased collagen density at seven and 14 days, supporting increased wound remodeling and tissue regeneration, and
  • Reduced angiogenesis after wound closure (day 14), which is beneficial in preventing fibrosis.

About University of Texas Medical Branch at Galveston

Starting from the Texas City Disaster of 1947, the deadliest industrial accident in U.S. history and one of history’s largest non-nuclear explosions, UTMB clinicians and researchers in the Department of Surgery have developed treatments that improve the survival chances of patients with massive burns, reduce scar formation, and accelerate patient recovery. Many novel treatments discovered by UTMB researchers have been adopted by specialist burn centers around the world. The Department of Surgery’s Burn, Trauma, and Critical Care Research Laboratory is equipped with an array of cutting-edge equipment and technologies that support its research activities, including a dedicated cell culture suite, confocal microscope, flow cytometer, Comprehensive Lab Animal Monitoring System, and bioprinter for 3D cell culture.